Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High Following Strong Earnings

Key Points

• Shares of Kiniksa hit a new 52‑week high after Q1 results topped estimates — GAAP EPS $0.27 versus ~$0.18 expected and revenue $214.3M (+55% YoY), lifting the stock to about $54 on heavy volume.
• Management raised FY‑2026 net product revenue guidance to $930–$945M (above consensus) driven by strong ARCALYST sales, while Jefferies raised its price target to $71 and the company ended the quarter with roughly $468.1M in cash.
• Kiniksa also has near‑term clinical catalysts: KPL‑387 Phase 2 data are expected in 2H‑2026 with a Phase 3 pivotal trial planned by year‑end, which could further drive valuation if positive.

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) hit a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $54.23 and last traded at $53.85, with a volume of 3029498 shares trading hands. The stock had previously closed at $43.61.

The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company had revenue of $214.27 million for the quarter, compared to analyst estimates of $207.12 million. During the same quarter in the prior year, the business posted $0.11 EPS. Kiniksa Pharmaceuticals International's quarterly revenue was up 55.5% on a year-over-year basis.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 results beat expectations — GAAP EPS of $0.27 (versus street ~ $0.18–$0.21) and revenue of $214.3M, up ~55% year-over-year, demonstrating solid top- and bottom-line execution. KNSA Tops Q1 Earnings and Revenue Estimates (Zacks)
• Positive Sentiment: Company raised FY‑2026 net product revenue guidance to $930M–$945M (above consensus ~ $912.7M), signaling confidence in continued ARCALYST sales momentum. Kiniksa Reports Q1 Results and Portfolio Execution (GlobeNewswire)
• Positive Sentiment: ARCALYST product strength: Q1 net product revenue ~$214.3M (≈56% YoY growth); management increased ARCALYST 2026 expectations — core driver of revenue upside. Kiniksa Q1 Product Revenue Details (GlobeNewswire)
• Positive Sentiment: Pipeline catalysts: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026, with a Phase 3 pivotal trial planned to start by year‑end — potential near‑term clinical catalysts. KPL‑387 Development Update (GlobeNewswire)
• Positive Sentiment: Analyst upgrade/price target lift: Jefferies raised its price target from $58 to $71 and reiterated a buy rating, providing an institutional endorsement that supports further upside. Jefferies Raises KNSA Price Target (TickerReport)
• Positive Sentiment: Balance sheet: cash increased to ~$468.1M at quarter‑end, giving the company capital to fund growth and trials without immediate financing risk. Q1 Cash Balance (GlobeNewswire)
• Neutral Sentiment: Analyst expectations: the consensus outlook cited in reports implies expected FY EPS ~1.09; while Q1 beat supports that view, investors will watch whether margin trends and R&D timing sustain consensus. Earnings Call Transcript (Seeking Alpha)

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a research note on Sunday. Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the stock an "outperform" rating in a research note on Thursday, April 16th. Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research note on Friday, April 17th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.43.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 6,625 shares of the company's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares of the company's stock, valued at approximately $1,280,146.42. This represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 7,278 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $50.01, for a total transaction of $363,972.78. Following the sale, the chief executive officer directly owned 7,278 shares of the company's stock, valued at approximately $363,972.78. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,479 shares of company stock worth $2,832,812 in the last quarter. 53.48% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently modified their holdings of the company. Inspire Investing LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $1,698,000. Cannon Global Investment Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $530,000. SG Americas Securities LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 18.2% during the 1st quarter. SG Americas Securities LLC now owns 640,179 shares of the company's stock worth $30,825,000 after buying an additional 98,783 shares during the period. Virtu Financial LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth $267,000. Finally, Invesco Ltd. boosted its holdings in shares of Kiniksa Pharmaceuticals International by 25.9% during the 4th quarter. Invesco Ltd. now owns 32,334 shares of the company's stock worth $1,334,000 after buying an additional 6,656 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Trading Up 23.5%

The company's fifty day moving average is $46.11 and its 200-day moving average is $42.97. The firm has a market capitalization of $4.12 billion, a P/E ratio of 72.77 and a beta of 0.06.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.